Dr. Vidal on the Use of CDK4/6 Inhibitors in HER2+ Breast Cancer

Video

In Partnership With:

Gregory Vidal, MD, PhD, assistant professor, Department of Hematology/Oncology, The University of Tennessee Health Science Center, and medical oncologist, West Cancer Center, discusses the potential use of CDK4/6 inhibitors in HER2-positive breast cancer.

Gregory Vidal, MD, PhD, assistant professor, Department of Hematology/Oncology, The University of Tennessee Health Science Center, and medical oncologist, West Cancer Center, discusses the potential use of CDK4/6 inhibitors in HER2-positive breast cancer.

At the 2019 ESMO Congress, Sara Tolaney, MD, MPH, of Dana-Farber Cancer Institute, presented data from the phase II monarcHER trial with trastuzumab (Herceptin), abemaciclib (Verzenio), and fulvestrant (Faslodex) in women with hormone receptor—positive, HER2-positive breast cancer. The regimen was compared with standard of care trastuzumab and chemotherapy. A third cohort received abemaciclib and trastuzumab without fulvestrant.

The data showed an improvement in progression-free survival and objective response rates with the triplet versus the other options. CDK4/6 inhibitors have shown exceptional responses in the estrogen receptor—positive space, so it is not surprising that they are proving effective in the HER2-positive space as well, concludes Vidal.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute